JZP-361 is a potent, reversible and selective inhibitor of human recombinantMAGL(hMAGL) with anIC₅₀of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research^[1].

JZP-361 has almost 150-fold higher selectivity over human recombinant fatty acid amide hydrolase (hFAAH, IC₅₀= 7.24 μM) and 35-fold higher selectivity over human α/β-hydrolase-6 (hABHD6, IC₅₀= 1.79 μM)^[1].
JZP-361 retains H₁antagonistic affinity (pA2 = 6.81) but did not show cannabinoid receptor activity, when tested at concentrations ≤10 μM^[1].
JZP-361 displays favorable interactions within the active site of hMAGL including the important hydrogen-bonding of the carbonyl oxygen to the oxyanion hole^[1].

405.88

C₂₂H₂₀ClN₅O

1680193-80-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.